Cargando…

Gut Microbiota in Untreated Diffuse Large B Cell Lymphoma Patients

Intestinal microecology plays an important role in the development and progression of hematological malignancies. However, characteristics of gut microbiota in diffuse large B cell lymphoma (DLBCL) have not been reported. The microbiota composition of fecal samples from 25 untreated DLBCL patients a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Li, Wang, Wei, Zhang, Wei, Zhang, Yan, Wei, Chong, Li, Jingnan, Zhou, Daobin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076791/
https://www.ncbi.nlm.nih.gov/pubmed/33927704
http://dx.doi.org/10.3389/fmicb.2021.646361
_version_ 1783684758129082368
author Yuan, Li
Wang, Wei
Zhang, Wei
Zhang, Yan
Wei, Chong
Li, Jingnan
Zhou, Daobin
author_facet Yuan, Li
Wang, Wei
Zhang, Wei
Zhang, Yan
Wei, Chong
Li, Jingnan
Zhou, Daobin
author_sort Yuan, Li
collection PubMed
description Intestinal microecology plays an important role in the development and progression of hematological malignancies. However, characteristics of gut microbiota in diffuse large B cell lymphoma (DLBCL) have not been reported. The microbiota composition of fecal samples from 25 untreated DLBCL patients and 26 healthy volunteers was examined by 16S rRNA gene sequencing. On α-diversity analysis, there was no significant difference in species diversity and abundance between the two groups. However, a significant difference was observed on β-diversity analysis. The intestinal microbiota in patients with DLBCL showed a continuous evolutionary relationship, which progressed from phylum, proteobacteria, to genus, Escherichia-Shigella. Their abundance was significantly higher than that of the control group. At the genus level, Allisonella, lachnospira, and Roseburia were more abundant in patients with DLBCL than in the control group. Functional prediction by PICRUSt indicated that thiamine metabolism and phenylalanine, tyrosine, and tryptophan biosynthesis were significantly lower in the DLBCL group than in the control group. In conclusion, our results clearly demonstrate that the gut microbiota was changed significantly in DLBCL. The study highlights fundamental differences in the microbial diversity and composition of patients with DLBCL and paves the way for future prospective studies and microbiome-directed interventional trials to improve patient outcomes.
format Online
Article
Text
id pubmed-8076791
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80767912021-04-28 Gut Microbiota in Untreated Diffuse Large B Cell Lymphoma Patients Yuan, Li Wang, Wei Zhang, Wei Zhang, Yan Wei, Chong Li, Jingnan Zhou, Daobin Front Microbiol Microbiology Intestinal microecology plays an important role in the development and progression of hematological malignancies. However, characteristics of gut microbiota in diffuse large B cell lymphoma (DLBCL) have not been reported. The microbiota composition of fecal samples from 25 untreated DLBCL patients and 26 healthy volunteers was examined by 16S rRNA gene sequencing. On α-diversity analysis, there was no significant difference in species diversity and abundance between the two groups. However, a significant difference was observed on β-diversity analysis. The intestinal microbiota in patients with DLBCL showed a continuous evolutionary relationship, which progressed from phylum, proteobacteria, to genus, Escherichia-Shigella. Their abundance was significantly higher than that of the control group. At the genus level, Allisonella, lachnospira, and Roseburia were more abundant in patients with DLBCL than in the control group. Functional prediction by PICRUSt indicated that thiamine metabolism and phenylalanine, tyrosine, and tryptophan biosynthesis were significantly lower in the DLBCL group than in the control group. In conclusion, our results clearly demonstrate that the gut microbiota was changed significantly in DLBCL. The study highlights fundamental differences in the microbial diversity and composition of patients with DLBCL and paves the way for future prospective studies and microbiome-directed interventional trials to improve patient outcomes. Frontiers Media S.A. 2021-04-13 /pmc/articles/PMC8076791/ /pubmed/33927704 http://dx.doi.org/10.3389/fmicb.2021.646361 Text en Copyright © 2021 Yuan, Wang, Zhang, Zhang, Wei, Li and Zhou. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Yuan, Li
Wang, Wei
Zhang, Wei
Zhang, Yan
Wei, Chong
Li, Jingnan
Zhou, Daobin
Gut Microbiota in Untreated Diffuse Large B Cell Lymphoma Patients
title Gut Microbiota in Untreated Diffuse Large B Cell Lymphoma Patients
title_full Gut Microbiota in Untreated Diffuse Large B Cell Lymphoma Patients
title_fullStr Gut Microbiota in Untreated Diffuse Large B Cell Lymphoma Patients
title_full_unstemmed Gut Microbiota in Untreated Diffuse Large B Cell Lymphoma Patients
title_short Gut Microbiota in Untreated Diffuse Large B Cell Lymphoma Patients
title_sort gut microbiota in untreated diffuse large b cell lymphoma patients
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076791/
https://www.ncbi.nlm.nih.gov/pubmed/33927704
http://dx.doi.org/10.3389/fmicb.2021.646361
work_keys_str_mv AT yuanli gutmicrobiotainuntreateddiffuselargebcelllymphomapatients
AT wangwei gutmicrobiotainuntreateddiffuselargebcelllymphomapatients
AT zhangwei gutmicrobiotainuntreateddiffuselargebcelllymphomapatients
AT zhangyan gutmicrobiotainuntreateddiffuselargebcelllymphomapatients
AT weichong gutmicrobiotainuntreateddiffuselargebcelllymphomapatients
AT lijingnan gutmicrobiotainuntreateddiffuselargebcelllymphomapatients
AT zhoudaobin gutmicrobiotainuntreateddiffuselargebcelllymphomapatients